Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements.
biomarker
cardiovascular disease risk
cholesterol
lipoprotein(a)
low density lipoprotein
therapy
Journal
Journal of lipid research
ISSN: 1539-7262
Titre abrégé: J Lipid Res
Pays: United States
ID NLM: 0376606
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
07
2020
revised:
03
02
2021
accepted:
18
02
2021
pubmed:
27
2
2021
medline:
11
3
2022
entrez:
26
2
2021
Statut:
ppublish
Résumé
Current methods for determining "LDL-C" in clinical practice measure the cholesterol content of both LDL and lipoprotein(a) [Lp(a)-C]. We developed a high-throughput, sensitive, and rapid method to quantitate Lp(a)-C and improve the accuracy of LDL-C by subtracting for Lp(a)-C (LDL-C
Identifiants
pubmed: 33636163
pii: S0022-2275(21)00034-1
doi: 10.1016/j.jlr.2021.100053
pmc: PMC8042377
pii:
doi:
Substances chimiques
Cholesterol, LDL
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100053Subventions
Organisme : NHLBI NIH HHS
ID : K08 HL150271
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL148188
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001442
Pays : United States
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest Drs Tsimikas and Witztum are coinventors and receive royalties from patents owned by UCSD on oxidation-specific antibodies and of biomarkers related to oxidized lipoproteins and are cofounders and have equity interests in Oxitope, Inc. and Kleanthi Diagnostics, LLC. Although these relationships have been identified for conflict of interest management based on the overall scope of the project and its potential benefit to Oxitope and Kleanthi, the research findings included in this particular publication may not necessarily relate to the interests of Oxitope and Kleanthi. The terms of this arrangement have been reviewed and approved by the UCSD in accordance with its conflict of interest policies. Dr Tsimikas has a dual appointment at UCSD and Ionis Pharmaceuticals, and Dr Witztum is a consultant to Ionis Pharmaceuticals. The authors declare that they have no conflicts of interest with the contents of this article.